Abstract Background and Objective Sacubitril/valsartan improved the prognosis of patients
with heart failure with reduced ejection fraction in the PARADIGM-HF study. Recently, the …

Introduction: We investigated the effectiveness of sacubitril/valsartan by performing
laboratory tests and a 6-minute walking test (6-MWT) at 1 and 6 months after treatment …

Aims Large‐scale clinical trials have demonstrated clinical benefits of sacubitril–valsartan in
symptomatic heart failure with reduced ejection fraction patients (PARADIGM‐HF), with …

Acute decompensated heart failure (ADHF) is one of the conditions associated with high
rates of mortality and morbidity, in addition to its economic burden. Sacubitril/valsartan, the …

Aims Sacubitril/valsartan significantly reduced heart failure (HF) hospitalization and
cardiovascular mortality in a randomized controlled trial. However, little is known about real …

Introduction Sacubitril/valsartan has been established as an effective treatment for heart
failure (HF) with reduced ejection fraction based on clinical trial data; however, little is known …

Background The effectiveness and safety of initiating sacubitril/valsartan therapy among
patients who are hospitalized for acute heart failure (HF) is unclear. Methods A cohort of …

Background Sacubitril/valsartan (S/V) is indicated for the treatment of chronic heart failure
with reduced ejection fraction (HFrEF). The TRANSITION study aims to provide evidence of …

Importance The use of sacubitril/valsartan is not endorsed by practice guidelines for use in
patients with New York Heart Association class IV heart failure with a reduced ejection …

Aims Sacubitril/valsartan has shown efficacy and tolerability in patients with heart failure
(HF) and reduced ejection fraction (HFrEF) in the ambulatory setting (PARADIGM‐HF), and …